These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 33741892)

  • 1. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis.
    Vazquez R; Breal C; Zalmai L; Friedrich C; Almire C; Contejean A; Barreau S; Grignano E; Willems L; Deau-Fischer B; Franchi P; Vignon M; Decroocq J; Birsen R; Goldwirt L; Kaltenbach S; Couronne L; Fontenay M; Kosmider O; Bouscary D; Chapuis N
    Blood Cancer J; 2021 Mar; 11(3):62. PubMed ID: 33741892
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
    Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
    [No Abstract]   [Full Text] [Related]  

  • 4. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Gangat N; Tefferi A
    Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 7. New drugs approved for acute myeloid leukaemia in 2018.
    Kucukyurt S; Eskazan AE
    Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax-induced panniculitis in an acute myeloid leukemia patient.
    Liao PW; Wang RC; Chen TC; Teng CJ
    Ann Hematol; 2021 May; 100(5):1333-1334. PubMed ID: 33439305
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    DiNardo CD; Tiong IS; Quaglieri A; MacRaild S; Loghavi S; Brown FC; Thijssen R; Pomilio G; Ivey A; Salmon JM; Glytsou C; Fleming SA; Zhang Q; Ma H; Patel KP; Kornblau SM; Xu Z; Chua CC; Chen X; Blombery P; Flensburg C; Cummings N; Aifantis I; Kantarjian H; Huang DCS; Roberts AW; Majewski IJ; Konopleva M; Wei AH
    Blood; 2020 Mar; 135(11):791-803. PubMed ID: 31932844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?
    Foran JM
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101335. PubMed ID: 34865692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
    Jain P; Mims AS
    Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax with decitabine or azacitidine for AML.
    Das M
    Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
    [No Abstract]   [Full Text] [Related]  

  • 13. Can we selectively target AML stem cells?
    Jordan CT
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
    Jonas BA; Pollyea DA
    Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m
    Cortes J; Jonas BA; Schiller G; Mims A; Roboz GJ; Wei AH; Montesinos P; Ferrell PB; Yee KW; Fenaux P; Schwarer A; Watts JM
    Leuk Lymphoma; 2024 Aug; 65(8):1145-1152. PubMed ID: 38538632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
    Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
    Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the overall survival for older adults with AML finally improving?
    Lancet JE
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.